{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-24-000153","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.592953+00:00","generated_at":"2026-05-30T05:08:51.945750+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeoGenomics Q3 revenue up 10% to $168M; adjusted EBITDA up 305%, raises FY guidance to $37-40M","bullets":["Consolidated revenue $168M (+10% YoY); Clinical Services revenue $146M (+14%) with test volume +9%.","Net loss decreased 4% to $18M; adjusted EBITDA improved 305% to $13M, fifth consecutive positive quarter.","FY 2024 adjusted EBITDA guidance raised to $37-40M (from $33-37M); revenue guidance unchanged at $655-667M.","Board appointed Felicia Williams; initial equity award ~$140,000 vesting June 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-24-000153","json":"https://secwatch.observer/filing/0001077183-24-000153.json","markdown":"https://secwatch.observer/filing/0001077183-24-000153.md","text":"https://secwatch.observer/filing/0001077183-24-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/0001077183-24-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/neo-20241101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:08:51.945750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c464a4bb19","claim":"Felicia Williams was appointed as member of the Board at NEOGENOMICS INC.","evidence_excerpt":"On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/0001077183-24-000153-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}